An evaluation of the preprints produced at the beginning of the 2022 mpox public health emergency.
Monkeypox
Mpox
Peer-review
Preprint
Quality
Risk of bias
Journal
Research integrity and peer review
ISSN: 2058-8615
Titre abrégé: Res Integr Peer Rev
Pays: England
ID NLM: 101676020
Informations de publication
Date de publication:
07 Oct 2024
07 Oct 2024
Historique:
received:
22
02
2024
accepted:
13
09
2024
medline:
7
10
2024
pubmed:
7
10
2024
entrez:
6
10
2024
Statut:
epublish
Résumé
Preprints are scientific articles that have not undergone the peer-review process. They allow the latest evidence to be rapidly shared, however it is unclear whether they can be confidently used for decision-making during a public health emergency. This study aimed to compare the data and quality of preprints released during the first four months of the 2022 mpox outbreak to their published versions. Eligible preprints (n = 76) posted between May to August 2022 were identified through an established mpox literature database and followed to July 2024 for changes in publication status. Quality of preprints and published studies was assessed by two independent reviewers to evaluate changes in quality, using validated tools that were available for the study design (n = 33). Tools included the Newcastle-Ottawa Scale; Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2); and JBI Critical Appraisal Checklists. The questions in each tool led to an overall quality assessment of high quality (no concerns with study design, conduct, and/or analysis), moderate quality (minor concerns) or low quality (several concerns). Changes in data (e.g. methods, outcomes, results) for preprint-published pairs (n = 60) were assessed by one reviewer and verified by a second. Preprints and published versions that could be evaluated for quality (n = 25 pairs) were mostly assessed as low quality. Minimal to no change in quality from preprint to published was identified: all observational studies (10/10), most case series (6/7) and all surveillance data analyses (3/3) had no change in overall quality, while some diagnostic test accuracy studies (3/5) improved or worsened their quality assessment scores. Among all pairs (n = 60), outcomes were often added in the published version (58%) and less commonly removed (18%). Numerical results changed from preprint to published in 53% of studies, however most of these studies (22/32) had changes that were minor and did not impact main conclusions of the study. This study suggests the minimal changes in quality, results and main conclusions from preprint to published versions supports the use of preprints, and the use of the same critical evaluation tools on preprints as applied to published studies, in decision-making during a public health emergency.
Sections du résumé
BACKGROUND
BACKGROUND
Preprints are scientific articles that have not undergone the peer-review process. They allow the latest evidence to be rapidly shared, however it is unclear whether they can be confidently used for decision-making during a public health emergency. This study aimed to compare the data and quality of preprints released during the first four months of the 2022 mpox outbreak to their published versions.
METHODS
METHODS
Eligible preprints (n = 76) posted between May to August 2022 were identified through an established mpox literature database and followed to July 2024 for changes in publication status. Quality of preprints and published studies was assessed by two independent reviewers to evaluate changes in quality, using validated tools that were available for the study design (n = 33). Tools included the Newcastle-Ottawa Scale; Quality Assessment of Diagnostic Accuracy Studies 2 (QUADAS-2); and JBI Critical Appraisal Checklists. The questions in each tool led to an overall quality assessment of high quality (no concerns with study design, conduct, and/or analysis), moderate quality (minor concerns) or low quality (several concerns). Changes in data (e.g. methods, outcomes, results) for preprint-published pairs (n = 60) were assessed by one reviewer and verified by a second.
RESULTS
RESULTS
Preprints and published versions that could be evaluated for quality (n = 25 pairs) were mostly assessed as low quality. Minimal to no change in quality from preprint to published was identified: all observational studies (10/10), most case series (6/7) and all surveillance data analyses (3/3) had no change in overall quality, while some diagnostic test accuracy studies (3/5) improved or worsened their quality assessment scores. Among all pairs (n = 60), outcomes were often added in the published version (58%) and less commonly removed (18%). Numerical results changed from preprint to published in 53% of studies, however most of these studies (22/32) had changes that were minor and did not impact main conclusions of the study.
CONCLUSIONS
CONCLUSIONS
This study suggests the minimal changes in quality, results and main conclusions from preprint to published versions supports the use of preprints, and the use of the same critical evaluation tools on preprints as applied to published studies, in decision-making during a public health emergency.
Identifiants
pubmed: 39370503
doi: 10.1186/s41073-024-00152-w
pii: 10.1186/s41073-024-00152-w
doi:
Types de publication
Journal Article
Langues
eng
Pagination
11Informations de copyright
© 2024. Crown.
Références
Huisman J, Smits J. Duration and quality of the peer review process: the author’s perspective. Scientometrics. 2017;113(1):633–50.
doi: 10.1007/s11192-017-2310-5
COPE. COPE Discussion document: Preprints. 2018.
Guterman EL, Braunstein LZ. Preprints during the COVID-19 pandemic: Public Health Emergencies and Medical Literature. J Hosp Med. 2020;15(10):634–6.
doi: 10.12788/jhm.3491
Bero L, Lawrence R, Leslie L, Chiu K, McDonald S, Page MJ, et al. Cross-sectional study of preprints and final journal publications from COVID-19 studies: discrepancies in results reporting and spin in interpretation. BMJ Open. 2021;11(7):e051821.
doi: 10.1136/bmjopen-2021-051821
Brierley L, Nanni F, Polka JK, Dey G, Pálfy M, Fraser N, Coates JA. Tracking changes between preprint posting and journal publication during a pandemic. PLoS Biol. 2022;20(2):e3001285.
doi: 10.1371/journal.pbio.3001285
Spungen H, Burton J, Schenkel S, Schriger DL. Completeness and spin of medRxiv Preprint and Associated published abstracts of COVID-19 randomized clinical trials. JAMA. 2023;329(15):1310–2.
doi: 10.1001/jama.2023.1784
Pussegoda K, Corrin T, Baumeister A, Ayache D, Waddell L. Methods for conducting a living evidence profile on mpox: an evidence map of the literature. Cochrane Evid Synthesis Methods. 2024:e12044.
ProQuest. About RefWorks https://refworks.proquest.com/about-us/ .
DistillerSR. DistillerSR Smarter Reviews: Trusted Evidence DistillerSR Inc.2024 [updated 2024. https://www.distillersr.com/ ].
WHO. 2022-23 Mpox Outbreak: Global Trends: World Health Organization. 2023 [ https://worldhealthorg.shinyapps.io/mpx_global/ ].
Wells BS G, O’Connell, D, Robertson J, Welch JPV. ML, P. Tugwell. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. https://www.ohri.ca/programs/clinical_epidemiology/nosgen.pdf .
Ribeiro CM, Beserra BTS, Silva NG, Lima CL, Rocha PRS, Coelho MS, et al. Exposure to endocrine-disrupting chemicals and anthropometric measures of obesity: a systematic review and meta-analysis. BMJ Open. 2020;10(6):e033509.
doi: 10.1136/bmjopen-2019-033509
Herzog R, Álvarez-Pasquin MJ, Díaz C, Del Barrio JL, Estrada JM, Gil Á. Are healthcare workers’ intentions to vaccinate related to their knowledge, beliefs and attitudes? A systematic review. BMC Public Health. 2013;13(1):154.
doi: 10.1186/1471-2458-13-154
Whiting PF, Rutjes AWS, Westwood ME, et al. QUADAS-2: a revised Tool for the Quality Assessment of Diagnostic Accuracy studies. Annals of Internal Medicine; 2011.
Munn Z, Barker TH, Moola S, Tufanaru C, Stern C, McArthur A, et al. Methodological quality of case series studies: an introduction to the JBI critical appraisal tool. JBI Evid Synthesis. 2020;18(10):2127–33.
Munn Z, Moola S, Lisy K, Riitano D, Tufanaru C. Methodological guidance for systematic reviews of observational epidemiological studies reporting prevalence and cumulative incidence data. JBI Evid Implement. 2015;13(3):147–53.
Yinka-Ogunleye A. Monkeypox Risk and Mortality Associated with HIV infection: a National Case Control Study in Nigeria. SSRN - Lancet prepublication; 2022.
Yinka-Ogunleye A, Dalhat M, Akinpelu A, Aruna O, Garba F, Ahmad A et al. Mpox (monkeypox) risk and mortality associated with HIV infection: a national case-control study in Nigeria. BMJ Glob Health. 2023;8(11).
doi: 10.1136/bmjgh-2023-013126
Ahmed SK, Abdulqadir SO, Omar RM, Abdullah AJ, Rahman HA, Hussein SH, et al. Knowledge, attitude and worry in the Kurdistan Region of Iraq during the Mpox (Monkeypox) outbreak in 2022: an online cross-sectional study. Vaccines. 2023;11(3):610.
doi: 10.3390/vaccines11030610
Ahmed SK, Abdulqadirb SO, Omar RM, Essa RA, Hussein SH, Khdir AA, Abdulla AQ. Study of knowledge, attitude and anxiety in Kurdistan-region of Iraqi population during the monkeypox outbreak in 2022. Research Square; 2022.
Aljamaan F, Alenezi S, Alhasan K, Saddik B, Alhaboob A, Altawil E, et al. Healthcare workers’ worries and Monkeypox vaccine advocacy during the first month of the WHO Monkeypox alert: cross-sectional survey in Saudi Arabia. medRxiv; 2022.
Aljamaan F, Alenezi S, Alhasan K, Saddik B, Alhaboob A, Altawil ES, et al. Healthcare Workers’ worries and Monkeypox Vaccine Advocacy during the First Month of the WHO Monkeypox Alert: cross-sectional survey in Saudi Arabia. Vaccines. 2022;10(9):1408.
doi: 10.3390/vaccines10091408
Alshahrani N, Algethami M, Alarifi A, Alzahrani F, Sheerah HA, Abdelaal A, et al. Knowledge and attitude regarding monkeypox virus among physicians in Saudi Arabia, a cross-sectional study. Research Square; 2022.
Alshahrani NZ, Algethami MR, Alarifi AM, Alzahrani F, Alshehri EA, Alshehri AM, et al. Knowledge and attitude regarding Monkeypox Virus among Physicians in Saudi Arabia: a cross-sectional study. Vaccines. 2022;10(12):2099.
doi: 10.3390/vaccines10122099
Winters M, Malik AA, Omer SB. Attitudes towards Monkeypox vaccination and predictors of vaccination intentions among the US general public. PLoS ONE. 2022;17(12):e0278622.
doi: 10.1371/journal.pone.0278622
Malik AA, Winters MS, Omer SB. Attitudes of the US general public towards Monkeypox. medRxiv. 2022:2022.06.20.22276527.
Wang H, Abreu de Paulo KJI, Gultzow T, Zimmermann HML, Jonas K. Monkeypox self-diagnosis abilities, determinants of vaccination intention and self-isolation intention after diagnosis among MSM in the Netherlands. medRxiv; 2022.
doi: 10.1101/2022.07.29.22278167
Wang H, apos, Abreu de Paulo KJI, Gültzow T, Zimmermann HML, Jonas KJ. Monkeypox self-diagnosis abilities, determinants of vaccination and self-isolation intention after diagnosis among MSM, the Netherlands, July 2022. Eurosurveillance. 2022;27(33):2200603.
doi: 10.2807/1560-7917.ES.2022.27.33.2200603
Wang H, Abreu de Paulo KJI, Gulzow T, Zimmermann HML, Jonas K. Brief report: determinants of potential sexual activity reduction in the face of the Monkeypox epidemic. medRxiv; 2022.
De Baetselier I, Van Dijck C, Kenyon C, Coppens J, Michiels J, de Block T, et al. Retrospective detection of asymptomatic monkeypox virus infections among male sexual health clinic attendees in Belgium. Nat Med. 2022;28(11):2288–92.
doi: 10.1038/s41591-022-02004-w
De Baetselier I, Van Dijck C, Kenyon C, Coppens J, Van den Bossche D, Smet H, et al. Asymptomatic Monkeypox Virus Infections among Male Sexual Health Clinic Attendees in Belgium. SSRN - Lancet prepublication; 2022.
Arbel R, Sagy YW, Zucker R, Arieh NG, Markovits H, Abu-Ahmad W, et al. Vaccine effectiveness of modified Vaccinia Ankara in Human Monkeypox. Research Square; 2022.
doi: 10.21203/rs.3.rs-1976861/v1
Zucker R, Lavie G, Sagy YW, Arieh NG, Markovits H, Abu-Ahmad W et al. Risk Assessment of Human Monkeypox Infections for Vaccine Prioritization. Research Square; 2022.
Temsah M-H, Aljamaan F, Alenezi S, Alhasan K, Saddik B, Al-Barrag A et al. Monkeypox caused less worry than COVID-19 among the general population during the first month of the WHO Monkeypox alert. medRxiv. 2022:2022.07.07.22277365.
Temsah M-H, Aljamaan F, Alenezi S, Alhasan K, Saddik B, Al-Barag A, et al. Monkeypox caused less worry than COVID-19 among the general population during the first month of the WHO Monkeypox alert: experience from Saudi Arabia. Travel Med Infect Dis. 2022;49:102426.
doi: 10.1016/j.tmaid.2022.102426
Wang H, de Paulo K, Gltzow T, Zimmermann HML, Jonas KJ. Brief report: determinants of potential sexual activity reduction in the Face of the Mpox Epidemic. Int J Behav Med. 2024;20240117.
Zucker R, Lavie G, Sagy YW, Arieh NG, Markovits H, Ahmad WA et al. Risk assessment of human mpox infections: retrospective cohort study. Clin Microbiol Infect. 2023;20230425.
Girometti N, Byrne R, Bracchi M, Heskin J, McOwan A, Tittle V, et al. Epidemiological characteristics and clinical features of confirmed human monkeypox virus cases in individuals attending a Sexual Health Centre in London, United Kingdom. SSRN - Lancet prepublication; 2022.
doi: 10.2139/ssrn.4125251
Girometti N, Byrne R, Bracchi M, Heskin J, McOwan A, Tittle V, et al. Demographic and clinical characteristics of confirmed human monkeypox virus cases in individuals attending a sexual health centre in London, UK: an observational analysis. Lancet Infect Dis. 2022;22(9):1321–8.
doi: 10.1016/S1473-3099(22)00411-X
Noe S, Zange S, Seilmaier M. Clinical and virological features of first human monkeypox cases in Germany. Research Square prepub; 2022.
doi: 10.21203/rs.3.rs-1725831/v1
Noe S, Zange S, Seilmaier M, Antwerpen MH, Fenzl T, Schneider J, et al. Clinical and virological features of first human monkeypox cases in Germany. Infection. 2023;51(1):265–70.
doi: 10.1007/s15010-022-01874-z
Patalon T, Perez G, Melamed G. Monkeypox infection in a developed country: a Case Report. Research Square prepub; 2022.
Patalon T, Perez G, Melamed G, Wolf T, Gazit S. Mpox Infection in a developed country: a Case Report. Trop Med Infect Disease. 2023;8(1):15.
doi: 10.3390/tropicalmed8010015
Pittman PR, Martin JW, Kingebeni PM, Tamfum J-JM, Mwema G, Wan Q, et al. Clinical characterization and placental pathology of mpox infection in hospitalized patients in the Democratic Republic of the Congo. PLoS Negl Trop Dis. 2023;17(4):e0010384.
doi: 10.1371/journal.pntd.0010384
Pittman PR, Martin JW, Kingebeni PM, Tamfum J-JM, Wan Q, Reynolds MG et al. Clinical characterization of human monkeypox infections in the Democratic Republic of the Congo. medRxiv. 2022:2022.05.26.22273379.
Tarín-Vicente EJ, Agud-Dios M, Alemany A, Ubals M, Suñer C, Antón A, et al. Clinical presentation and Virological Assessment of Confirmed Human Monkeypox Virus Cases in Spain: a prospective cohort study. SSRN - Lancet prepublication; 2022.
Tarín-Vicente EJ, Alemany A, Agud-Dios M, Ubals M, Suñer C, Antón A, et al. Clinical presentation and virological assessment of confirmed human monkeypox virus cases in Spain: a prospective observational cohort study. Lancet. 2022;400(10353):661–9.
doi: 10.1016/S0140-6736(22)01436-2
Thy M, Peiffer-Smadja N, Mailhe M, Kramer L, Ferré VM, Houhou N, et al. Breakthrough infections after Postexposure Vaccination against Mpox. N Engl J Med. 2022;387(26):2477–9.
doi: 10.1056/NEJMc2211944
Thy M, Peiffer-Smadja N, Mailhe M, Kramer L, Ferré VM, Houhou-Fidouh N, et al. Breakthrough infections after post-exposure vaccination against Monkeypox. medRxiv; 2022.
doi: 10.1101/2022.08.03.22278233
Yadav P, Reghukumar A, Sahay R, Shete KS, Raman A. A, et al. First two cases of Monkeypox virus infection in travellers returned from UAE to India, July 2022. Research Square; 2022.
Yadav PD, Reghukumar A, Sahay RR, Shete KS, Raman AM. First two cases of Monkeypox virus infection in travellers returned from UAE to India, July 2022. J Infect. 2022;85(5):e145–8.
doi: 10.1016/j.jinf.2022.08.007
Charniga K, Masters NB, Slayton RB, Gosdin L, Minhaj FS, Philpott D et al. Estimating the incubation period of monkeypox virus during the 2022 multi-national outbreak. medRxiv. 2022:2022.06.22.22276713.
de Jonge E, Peterse C, Koelewijn J, van der Drift A-M, van der Beek R, Nagelkerke E, Lodder W. The detection of Monkeypox Virus DNA in Wastewater samples in the Netherlands. SSRN - Lancet prepublication; 2022.
de Jonge EF, Peterse CM, Koelewijn JM, van der Drift A-MR, van der Beek RFHJ, Nagelkerke E, Lodder WJ. The detection of monkeypox virus DNA in wastewater samples in the Netherlands. Sci Total Environ. 2022;852:158265.
doi: 10.1016/j.scitotenv.2022.158265
Miura F, van Ewijk CE, Backer JA, Xiridou M, Franz E, e Coul EO et al. The incubation period for monkeypox cases confirmed in the Netherlands, May 2022. medRxiv. 2022:2022.06.09.22276068.
Miura F, van Ewijk CE, Backer JA, Xiridou M, Franz E, Op de Coul E, et al. Estimated incubation period for monkeypox cases confirmed in the Netherlands, May 2022. Eurosurveillance. 2022;27(24):2200448.
doi: 10.2807/1560-7917.ES.2022.27.24.2200448
Wurtzer S, Levert M, Dhenain E, Boni M, Tournier JN, Londinsky N, et al. First Detection of Monkeypox Virus Genome in Sewersheds in France: the potential of Wastewater-based epidemiology for Monitoring Emerging Disease. Environ Sci Technol Lett. 2022;9(11):991–6.
doi: 10.1021/acs.estlett.2c00693
Wurtzer S, Levert M, Dhenain E, Boni M, Tournier JN, Londinsky N, et al. First detection of Monkeypox virus genome in sewersheds in France. medRxiv; 2022.
doi: 10.1101/2022.08.18.22278938
Ali SN, Ahmed T, Paul J. Monkeypox Skin Lesion Detection Using Deep Learning Models: A Feasibility Study. ArXiv. 2022.
Allan-Blitz L, Carragher K, Sukhija-Cohen A, Li H, Klausner J. Laboratory Validation and clinical implementation of human monkeypox saliva-based tests. medRxiv; 2022.
doi: 10.1101/2022.08.08.22278498
Allan-Blitz L-T, Carragher K, Sukhija-Cohen A, Ritchie P, Scott H, Li H, Klausner JD. Laboratory validation and clinical performance of a saliva-based test for monkeypox virus. J Med Virol. 2023;95(1):e28191.
doi: 10.1002/jmv.28191
Bhadra S, Ellington A. Portable nucleic acid tests for rapid detection of monkeypox virus. medRxiv; 2022.
doi: 10.1101/2022.08.09.22278605
Islam T, Hussain MA, Chowdhury FUH, Islam R. Can Artificial Intelligence Detect Monkeypox from Digital skin. Images?: bioRxiv; 2022.
doi: 10.1101/2022.08.08.503193
La Rosa G, Mancini P, Veneri C, Bonanno Ferraro G, Lucentini L, Iaconelli M, Suffredini E. Detection of Monkeypox virus DNA in the wastewater of an airport in Rome, Italy: expanding environmental surveillance to emerging threats. medRxiv; 2022.
La Rosa G, Mancini P, Veneri C, Ferraro GB, Lucentini L, Iaconelli M, Suffredini E. Detection of Monkeypox Virus DNA in Airport Wastewater, Rome, Italy. Emerg Infect Disease J. 2023;29(1):193.
doi: 10.3201/eid2901.221311
Wang Z, Tober-Lau P, Farztdinov V, Lemke O, Schwecke T, Steinbrecher S, et al. The human host response to monkeypox infection: a proteomic case series study. medRxiv; 2022.
Wang Z, Tober-Lau P, Farztdinov V, Lemke O, Schwecke T, Steinbrecher S, et al. The human host response to monkeypox infection: a proteomic case series study. EMBO Mol Med. 2022;14(11):e16643.
doi: 10.15252/emmm.202216643
Wawina-Bokalanga T, Sklenovska N, Vanmechelen B, Bloemen M, Vergote V, Laenen L et al. An accurate and rapid real-time PCR approach for human Monkeypox virus diagnosis. medRxiv. 2022:2022.06.23.22276033.
Wolfe M, Duong D, Hughes B, Chan-Herur V, White B, Boehm A. Detection of monkeypox viral DNA in a routine wastewater monitoring program. medRxiv; 2022.
doi: 10.1101/2022.07.25.22278043
Wu F, Oghuan J, Gitter A, Mena KD, Brown EL. Wide mismatches in the sequences of primers and probes for monkeypox virus diagnostic assays. J Med Virol. 2023;95(1):e28395.
doi: 10.1002/jmv.28395
Albin J, Lazarus J, Hysell K, Rubins D, Germaine L, Dugdale C, et al. Development and implementation of a clinical decision support system tool for the evaluation of suspected monkeypox infection. medRxiv; 2022.
Albin JS, Lazarus JE, Hysell KM, Rubins DM, Germaine L, Dugdale CM, et al. Development and implementation of a clinical decision support system tool for the evaluation of suspected monkeypox infection. J Am Med Inform Assoc. 2022;29(12):2124–7.
doi: 10.1093/jamia/ocac151
Nörz D, Tang HT, Emmerich P, Giersch K, Fischer N, Addo MM et al. Rapid adaptation of established high-throughput molecular testing infrastructure for detection of monkeypoxvirus. medRxiv. 2022:2022.06.05.22276011.
Nörz D, Tang HT, Emmerich P, Giersch K, Fischer N, Schmiedel S, et al. Rapid Adaptation of established high-throughput Molecular Testing infrastructure for Monkeypox Virus Detection. Emerg Infect Disease J. 2022;28(9):1765.
doi: 10.3201/eid2809.220917
Gigante CM, Korber B, Seabolt MH, Wilkins K, Davidson W, Rao AK et al. Multiple lineages of Monkeypox virus detected in the United States, 2021–2022. bioRxiv. 2022:2022.06.10.495526.
Gigante CM, Korber B, Seabolt MH, Wilkins K, Davidson W, Rao AK, et al. Multiple lineages of monkeypox virus detected in the United States, 2021–2022. Science. 2022;378(6619):560–5.
doi: 10.1126/science.add4153
Batéjat C, Grassin Q, Feher M, Hoinard D, Vanhomwegen J, Manuguerra J-C, Leclercq I. Heat inactivation of the Monkeypoxvirus. bioRxiv; 2022.
Batéjat C, Grassin Q, Feher M, Hoinard D, Vanhomwegen J, Manuguerra J-C, Leclercq I. Heat inactivation of monkeypox virus. J Biosaf Biosecur. 2022;4(2):121–3.
doi: 10.1016/j.jobb.2022.08.001
Paran N, Yahalom-Ronen Y, Shifman O, Lazar S, Ben-Ami R, Yakubovsky M, et al. Monkeypox DNA correlates with virus infectivity in clinical samples. bioRxiv; 2022.
doi: 10.1101/2022.08.02.502454
Paran N, Yahalom-Ronen Y, Shifman O, Lazar S, Ben-Ami R, Yakubovsky M, et al. Monkeypox DNA levels correlate with virus infectivity in clinical samples, Israel, 2022. Eurosurveillance. 2022;27(35):2200636.
doi: 10.2807/1560-7917.ES.2022.27.35.2200636
Du Z, Shao Z, Bai Y, Wang L, Herrera-Diestra J, Fox S, et al. Reproduction number of monkeypox in the early stage of the 2022 multi-country outbreak. medRxiv; 2022.
Du Z, Shao Z, Bai Y, Wang L, Herrera-Diestra JL, Fox SJ et al. Reproduction number of monkeypox in the early stage of the 2022 multi-country outbreak. J Travel Med. 2022;29(8)taac099.
doi: 10.1093/jtm/taac099
Frenois-Veyrat G, Gallardo F, Gorgé O, Marcheteau E, Ferraris O, Baidaliuk A et al. Tecovirimat is highly efficient on the Monkeypox virus lineage responsible for the international 2022 outbreak. 2022.
Frenois-Veyrat G, Gallardo F, Gorgé O, Marcheteau E, Ferraris O, Baidaliuk A, et al. Tecovirimat is effective against human monkeypox virus in vitro at nanomolar concentrations. Nat Microbiol. 2022;7(12):1951–5.
doi: 10.1038/s41564-022-01269-8
Van Dijck C, Hens N, Kenyon C, Tsoumanis A. The roles of unrecognized monkeypox cases, contact isolation and vaccination in determining epidemic size in Belgium. A modelling study. medRxiv; 2022.
Van Dijck C, Hens N, Kenyon C, Tsoumanis A. The roles of unrecognized mpox cases, contact isolation and vaccination in determining epidemic size in Belgium: a modeling study. Clin Infect Dis. 2022;76(3):e1421–3.
doi: 10.1093/cid/ciac723
Yeh T-Y, Contreras G. Recombination shapes 2022 monkeypox outbreak. medRxiv; 2022.
Yeh T-Y, Hsieh Z-Y, Feehley MC, Feehley PJ, Contreras GP, Su Y-C, et al. Recombination shapes the 2022 monkeypox (mpox) outbreak. Med. 2022;3(12):824–6.
doi: 10.1016/j.medj.2022.11.003
Schrarstzhaupt IN. In: Fontes-Dutra M, Diaz-Quijano F, editors. Early estimates of the incidence trend and the reproductive number of the monkeypox epidemic in Brazil. medRxiv; 2022.
doi: 10.1016/j.tmaid.2022.102484
Schrarstzhaupt IN, Fontes-Dutra M, Diaz-Quijano FA. Early estimates of the incidence trend and the reproductive number of the monkeypox epidemic in Brazil. Travel Med Infect Dis. 2022;50:102484.
doi: 10.1016/j.tmaid.2022.102484
Sun Y-Q, Chen J-J, Liu M-C, Zhang Y-Y, Wang T, Che T-L, et al. Mapping global zoonotic niche and interregional transmission risk of Monkeypox: a retrospective observational study. SSRN - Lancet prepublication; 2022.
Sun YQ, Chen JJ, Liu MC, Zhang YY, Wang T, Che TL, et al. Mapping global zoonotic niche and interregional transmission risk of monkeypox: a retrospective observational study. Global Health. 2023;19(1):58.
doi: 10.1186/s12992-023-00959-0
Wu F, Oghuan J, Gitter A, Mena K, Brown E. Wide mismatches in the sequences of primers and probes for Monkeypox virus diagnostic assays. medRxiv; 2022.
doi: 10.1101/2022.08.10.22278644
Brand SPC, Cavallaro M, Cumming F, Turner C, Florence I, Blomquist P, et al. The role of vaccination and public awareness in forecasts of Mpox incidence in the United Kingdom. Nat Commun. 2023;14(1):4100.
doi: 10.1038/s41467-023-38816-8
Brand SPC, Cavallaro M, Hilton J, Guzman-Rincon L, House T, Keeling MJ, Nokes DJ. The role of vaccination and public awareness in medium-term forecasts of monkeypox incidence in the United Kingdom. medRxiv; 2022.
doi: 10.1101/2022.08.15.22278788
Gould S, Atkinson B, Onianwa O, Spencer A, Furneaux J, Grieves J, et al. Air and surface sampling for monkeypox virus in a UK hospital: an observational study. Lancet Microbe. 2022;3(12):e904–11.
doi: 10.1016/S2666-5247(22)00257-9
Gould S, Atkinson B, Onianwa O, Spencer A, Furneaux J, Grieves J, et al. Air and surface sampling for monkeypox virus in UK hospitals. medRxiv; 2022.
doi: 10.1101/2022.07.21.22277864
Ahmed SF, Sohail MS, Quadeer AA, McKay MR. Vaccinia virus vaccination is expected to elicit highly cross-reactive immunity to the 2022 monkeypox virus. bioRxiv. 2022:2022.06.23.497143.
Ahmed SF, Sohail MS, Quadeer AA, McKay MR. Vaccinia-Virus-based vaccines are expected to Elicit highly cross-reactive immunity to the 2022 Monkeypox Virus. Viruses [Internet]. 2022; 14(9):1960.
doi: 10.3390/v14091960
Lam HYI, Guan JS, Mu Y. In silico repurposed drugs against monkeypox virus. 2022.
Lam HYI, Guan JS, Mu Y. Silico Repurposed drugs against Monkeypox Virus. Molecules. 2022;27(16):5277.
doi: 10.3390/molecules27165277
Shantier S, Mustafa M, Abdelmoneim A, Fadl H, Elbager S, Makhawi A. Novel Multi Epitope-based vaccine against Monkeypox Virus: vaccinomic approach. Preprints.org; 2022.
Shantier SW, Mustafa MI, Abdelmoneim AH, Fadl HA, Elbager SG, Makhawi AM. Novel multi epitope-based vaccine against monkeypox virus: vaccinomic approach. Sci Rep. 2022;12(1):15983.
doi: 10.1038/s41598-022-20397-z
Giorgi FM, Pozzobon D, Di Meglio A, Mercatelli D. Genomic characterization of the recent monkeypox outbreak. bioRxiv. 2022:2022.06.01.494368.
Giorgi FM, Pozzobon D, Di Meglio A, Mercatelli D. Genomic and transcriptomic analysis of the recent Mpox outbreak. Vaccine. 2024;42(7):1841–9.
doi: 10.1016/j.vaccine.2023.12.086
Akazawa D, Ohashi H, Hishiki T, Morita T, Iwanami S, Kim KS, et al. Potential anti-monkeypox virus activity of atovaquone, mefloquine, and molnupiravir, and their potential use as treatments. bioRxiv; 2022.
doi: 10.1101/2022.08.02.502485
Akazawa D, Ohashi H, Hishiki T, Morita T, Iwanami S, Kim KS, et al. Potential Anti-mpox Virus Activity of Atovaquone, Mefloquine, and Molnupiravir, and their potential use as treatments. J Infect Dis. 2023;228(5):591–603.
doi: 10.1093/infdis/jiad058
Atkinson B, Burton C, Pottage T, Thompson K-A, Ngabo D, Crook A et al. Infection-competent monkeypox virus contamination identified in domestic settings following an imported case of monkeypox into the UK. medRxiv. 2022:2022.06.27.22276202.
Atkinson B, Burton C, Pottage T, Thompson K-A, Ngabo D, Crook A, et al. Infection-competent monkeypox virus contamination identified in domestic settings following an imported case of monkeypox into the UK. Environ Microbiol. 2022;24(10):4561–9.
doi: 10.1111/1462-2920.16129
Atkinson B, Gould S, Spencer A, Onianwa O, Furneaux J, Grieves J, et al. Monkeypox virus contamination in an office-based workplace environment, England 2022. medRxiv; 2022.
doi: 10.1101/2022.08.09.22278460
Atkinson B, Gould S, Spencer A, Onianwa O, Furneaux J, Grieves J, et al. Monkeypox virus contamination in an office-based workplace environment. J Hosp Infect. 2022;130:141–3.
doi: 10.1016/j.jhin.2022.08.009
Knight J, Tan DHS, Mishra S. Maximizing the impact of limited vaccine supply under different epidemic conditions: a two-city monkeypox modelling analysis. medRxiv; 2022.
Knight J, Tan DHS, Mishra S. Maximizing the impact of limited vaccine supply under different early epidemic conditions: a 2-city modelling analysis of monkeypox virus transmission among men who have sex with men. Can Med Assoc J. 2022;194(46):E1560–7.
doi: 10.1503/cmaj.221232
Gomes JP, Isidro J, Borges V. Multi-country outbreak of monkeypox virus: phylogenomic characterization and signs of microevolution. Research Square prepub; 2022.
Isidro J, Borges V, Pinto M, Sobral D, Santos JD, Nunes A, et al. Phylogenomic characterization and signs of microevolution in the 2022 multi-country outbreak of monkeypox virus. Nat Med. 2022;28(8):1569–72.
doi: 10.1038/s41591-022-01907-y
Kumar R, Nagar S, Haider S, Sood U, Ponnusamy K, Dhingra GG et al. Monkeypox virus: phylogenomics, host–pathogen interactome and mutational cascade. Microb Genomics. 2023;9(4):mgen000987.
doi: 10.1099/mgen.0.000987
Kumar R, Nagar S, Haider S, Sood U, Ponnusamy K, Dhingra GG, et al. Monkey pox virus (MPXV): phylogenomics, Host-Pathogen Interactome, and Mutational Cascade. bioRxiv; 2022.
Abrahim M, Guterres A, Costa Neves P, Cristina da AB, Ana PD. The emergence of new lineages of the Monkeypox virus could affect the 2022 outbreak. bioRxiv. 2022:2022.07.07.498743.
Yuan P, Tan Y, Yang L, Aruffo E, Ogden N, Belair J, et al. Modelling vaccination and control strategies of outbreaks of monkeypox at gatherings. medRxiv; 2022.
doi: 10.1101/2022.08.12.22278724
Yuan P, Tan Y, Yang L, Aruffo E, Ogden NH, Bélair J et al. Modeling vaccination and control strategies for outbreaks of monkeypox at gatherings. Front Public Health. 2022;10.
doi: 10.3389/fpubh.2022.1026489
Yuan P, Tan Y, Yang L, Aruffo E, Ogden NH, Belair J et al. Assessing transmission risks and control strategy for monkeypox as an emerging zoonosis in a metropolitan area. medRxiv. 2022:2022.06.28.22277038.
Yuan P, Tan Y, Yang L, Aruffo E, Ogden NH, Bélair J, et al. Assessing transmission risks and control strategy for monkeypox as an emerging zoonosis in a metropolitan area. J Med Virol. 2023;95(1):e28137.
doi: 10.1002/jmv.28137
Gu X, Zhang Y, Jiang W, Wang D, Lu J, Gu G et al. Protective human anti-poxvirus monoclonal antibodies are generated from rare memory B cells isolated by multicolor antigen tetramers. bioRxiv. 2022:2022.06.04.494786.
Gu X, Zhang Y, Jiang W, Wang D, Lu J, Gu G, et al. Protective human anti-poxvirus monoclonal antibodies are generated from rare memory B cells isolated by Multicolor Antigen tetramers. Vaccines. 2022;10(7):1084.
doi: 10.3390/vaccines10071084
Endo A, Murayama H, Abbott S, Ratnayake R, Pearson CAB, Edmunds WJ et al. Heavy-tailed sexual contact networks and the epidemiology of monkeypox outbreak in non-endemic regions, May 2022. medRxiv. 2022:2022.06.13.22276353.
Endo A, Murayama H, Abbott S, Ratnayake R, Pearson CAB, Edmunds WJ, et al. Heavy-tailed sexual contact networks and monkeypox epidemiology in the global outbreak, 2022. Science. 2022;378(6615):90–4.
doi: 10.1126/science.add4507
Brezis ES, Birukou A. Arbitrariness in the peer review process. Scientometrics. 2020;123(1):393–411.
doi: 10.1007/s11192-020-03348-1
De Vries DR, Marschall EA, Stein RA. Exploring the peer review process: what is it. Does it Work Can it Be Improved? Fisheries. 2009;34(6):270–9.
Maslove DM. Medical Preprints—A debate worth having. JAMA. 2018;319(5):443–4.
doi: 10.1001/jama.2017.17566
Flanagin A, Fontanarosa PB, Bauchner H. Preprints Involving Medical Research—Do the benefits outweigh the challenges? JAMA. 2020;324(18):1840–3.
doi: 10.1001/jama.2020.20674
Zeraatkar D, Pitre T, Leung G, Cusano E, Agarwal A, Khalid F, et al. Consistency of covid-19 trial preprints with published reports and impact for decision making: retrospective review. BMJ Med. 2022;1(1):e000309.
doi: 10.1136/bmjmed-2022-000309
COPE. COPE Retraction guidelines — English: Committee on Publication Ethics; 2019 [Version 2: November 2019: https://publicationethics.org/sites/default/files/retraction-guidelines-cope.pdf .
Fraser N, Brierley L, Dey G, Polka JK, Pálfy M, Nanni F, Coates JA. The evolving role of preprints in the dissemination of COVID-19 research and their impact on the science communication landscape. PLoS Biol. 2021;19(4):e3000959.
doi: 10.1371/journal.pbio.3000959